International Immunology, Vol. 13, No. 12, 1551-1559,
December 2001
© 2001 Japanese Society for Immunology
Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies
1 Cancer Immunobiology Center and
2 Center for Immunology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8576, USA
Correspondence to: E. S. Ward
Preclinical tests of therapeutic antibodies are frequently carried out in mice to evaluate pharmacokinetics and efficacy. However, the observation that mouse IgG are cleared rapidly from the human circulation suggests that mice may not always be an ideal model. The Fc receptor, FcRn, regulates the serum half-lives of IgG in mice and most likely has a similar function in humans. In the current study we have carried out an extensive analysis of the interaction of the human or mouse forms of FcRn with IgG from various species using surface plasmon resonance. We show that in contrast to mouse FcRn, human FcRn is surprisingly stringent in its binding specificity for IgG derived from different species. Human FcRn binds to human, rabbit and guinea pig IgG, but not significantly to rat, bovine, sheep or mouse IgG (with the exception of weak binding to mouse IgG2b). In contrast, mouse FcRn binds to all IgG analyzed. The lack of binding of human FcRn to mouse IgG1 has been confirmed using transfectants that have been engineered to express human FcRn on the cell surface. Our results provide a molecular explanation for the enigmatic observation that mouse IgG behave anomalously in humans. These studies have implications for the successful application of therapeutic antibodies.
Keywords: antibody, FcRn, interactions, promiscuity, therapeutic antibodies
3 Present address: Howard Hughes Medical Institute/UCLA, 675 Charles E. Young Drive South, Los Angeles, CA 90095, USA
Transmitting editor: D. Fearon
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-W. Qiao, K. Kobayashi, F.-E. Johansen, L. M. Sollid, J. T. Andersen, E. Milford, D. C. Roopenian, W. I. Lencer, and R. S. Blumberg Dependence of antibody-mediated presentation of antigen on FcRn PNAS, July 8, 2008; 105(27): 9337 - 9342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Mezo, K. A. McDonnell, C. A. T. Hehir, S. C. Low, V. J. Palombella, J. M. Stattel, G. D. Kamphaus, C. Fraley, Y. Zhang, J. A. Dumont, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn PNAS, February 19, 2008; 105(7): 2337 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. W. Kosterink, P. M. J. McLaughlin, M. N. Lub-de Hooge, H. H. Hendrikse, J. van Zanten, E. van Garderen, M. C. Harmsen, and L. F. M. H. de Leij Biodistribution Studies of Epithelial Cell Adhesion Molecule (EpCAM)-Directed Monoclonal Antibodies in the EpCAM-Transgenic Mouse Tumor Model J. Immunol., July 15, 2007; 179(2): 1362 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Mascelli, H. Zhou, R. Sweet, J. Getsy, H. M. Davis, M. Graham, and D. Abernethy Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development J. Clin. Pharmacol., May 1, 2007; 47(5): 553 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vaccaro, R. Bawdon, S. Wanjie, R. J. Ober, and E. S. Ward Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies PNAS, December 5, 2006; 103(49): 18709 - 18714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Petkova, S. Akilesh, T. J. Sproule, G. J. Christianson, H. Al Khabbaz, A. C. Brown, L. G. Presta, Y. G. Meng, and D. C. Roopenian Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease Int. Immunol., December 1, 2006; 18(12): 1759 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vidarsson, A. M. Stemerding, N. M. Stapleton, S. E. Spliethoff, H. Janssen, F. E. Rebers, M. de Haas, and J. G. van de Winkel FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis Blood, November 15, 2006; 108(10): 3573 - 3579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Dall'Acqua, P. A. Kiener, and H. Wu Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn) J. Biol. Chem., August 18, 2006; 281(33): 23514 - 23524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Lammerts van Bueren, W. K. Bleeker, H. O. Bogh, M. Houtkamp, J. Schuurman, J. G.J. van de Winkel, and P. W.H.I. Parren Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action. Cancer Res., August 1, 2006; 66(15): 7630 - 7638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-a. Yuan, H. H. Simmons, M. K. Robinson, M. Russeva, W. A. Marasco, and G. P. Adams Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol. Cancer Ther., August 1, 2006; 5(8): 2096 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kacskovics, Z. Kis, B. Mayer, A. P. West Jr, N. E. Tiangco, M. Tilahun, L. Cervenak, P. J. Bjorkman, R. A. Goldsby, O. Szenci, et al. FcRn mediates elongated serum half-life of human IgG in cattle Int. Immunol., April 1, 2006; 18(4): 525 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Maidji, S. McDonagh, O. Genbacev, T. Tabata, and L. Pereira Maternal Antibodies Enhance or Prevent Cytomegalovirus Infection in the Placenta by Neonatal Fc Receptor-Mediated Transcytosis Am. J. Pathol., April 1, 2006; 168(4): 1210 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Pagani, R. C. Reisin, and O. D. Uchitel Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. J. Neurosci., March 8, 2006; 26(10): 2661 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kenanova, T. Olafsen, D. M. Crow, G. Sundaresan, M. Subbarayan, N. H. Carter, D. N. Ikle, P. J. Yazaki, A. F. Chatziioannou, S. S. Gambhir, et al. Tailoring the Pharmacokinetics and Positron Emission Tomography Imaging Properties of Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments Cancer Res., January 15, 2005; 65(2): 622 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky, G. H. Schwartz, J. A. Gollob, J. A. Thompson, N. J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y.-P. Li, et al. Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer J. Clin. Oncol., August 1, 2004; 22(15): 3003 - 3015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Claypool, B. L. Dickinson, J. S. Wagner, F.-E. Johansen, N. Venu, J. A. Borawski, W. I. Lencer, and R. S. Blumberg Bidirectional Transepithelial IgG Transport by a Strongly Polarized Basolateral Membrane Fc{gamma}-Receptor Mol. Biol. Cell, April 1, 2004; 15(4): 1746 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Ober, C. Martinez, C. Vaccaro, J. Zhou, and E. S. Ward Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn J. Immunol., February 15, 2004; 172(4): 2021 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zocher, P. A. Baeuerle, T. Dreier, and A. Iglesias Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo Int. Immunol., July 1, 2003; 15(7): 789 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. O'Brien and S. B. Melville Multiple effects on Clostridium perfringens binding, uptake and trafficking to lysosomes by inhibitors of macrophage phagocytosis receptors Microbiology, June 1, 2003; 149(6): 1377 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Svitel, A. Balbo, R. A. Mariuzza, N. R. Gonzales, and P. Schuck Combined Affinity and Rate Constant Distributions of Ligand Populations from Experimental Surface Binding Kinetics and Equilibria Biophys. J., June 1, 2003; 84(6): 4062 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Roopenian, G. J. Christianson, T. J. Sproule, A. C. Brown, S. Akilesh, N. Jung, S. Petkova, L. Avanessian, E. Y. Choi, D. J. Shaffer, et al. The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs J. Immunol., April 1, 2003; 170(7): 3528 - 3533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Ward, J. Zhou, V. Ghetie, and R. J. Ober Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans Int. Immunol., February 1, 2003; 15(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Claypool, B. L. Dickinson, M. Yoshida, W. I. Lencer, and R. S. Blumberg Functional Reconstitution of Human FcRn in Madin-Darby Canine Kidney Cells Requires Co-expressed Human beta 2-Microglobulin J. Biol. Chem., July 26, 2002; 277(31): 28038 - 28050. [Abstract] [Full Text] [PDF]
|
|